CO6150167A2 - Analogos de 2-fenoxipirimidinona - Google Patents
Analogos de 2-fenoxipirimidinonaInfo
- Publication number
- CO6150167A2 CO6150167A2 CO09028167A CO09028167A CO6150167A2 CO 6150167 A2 CO6150167 A2 CO 6150167A2 CO 09028167 A CO09028167 A CO 09028167A CO 09028167 A CO09028167 A CO 09028167A CO 6150167 A2 CO6150167 A2 CO 6150167A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- amino
- mono
- independently selected
- cycloalkyl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 amino, hydroxy Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82325806P | 2006-08-23 | 2006-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6150167A2 true CO6150167A2 (es) | 2010-04-20 |
Family
ID=39107411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09028167A CO6150167A2 (es) | 2006-08-23 | 2009-03-18 | Analogos de 2-fenoxipirimidinona |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8003656B2 (enExample) |
| EP (1) | EP2061794B1 (enExample) |
| JP (1) | JP5421108B2 (enExample) |
| KR (1) | KR20090043583A (enExample) |
| CN (2) | CN101506210A (enExample) |
| AU (1) | AU2007288203B2 (enExample) |
| BR (1) | BRPI0716582A2 (enExample) |
| CA (1) | CA2660957C (enExample) |
| CO (1) | CO6150167A2 (enExample) |
| CR (1) | CR10675A (enExample) |
| EA (1) | EA200900330A1 (enExample) |
| ES (1) | ES2399928T3 (enExample) |
| GT (1) | GT200900040A (enExample) |
| IL (1) | IL197043A0 (enExample) |
| MA (1) | MA30720B1 (enExample) |
| MX (1) | MX2009002066A (enExample) |
| NI (1) | NI200900023A (enExample) |
| NO (1) | NO20091182L (enExample) |
| SV (1) | SV2009003173A (enExample) |
| TW (1) | TW200825089A (enExample) |
| WO (1) | WO2008024438A2 (enExample) |
| ZA (1) | ZA200901163B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| EA200900330A1 (ru) | 2006-08-23 | 2009-08-28 | Ньюроджен Корпорейшн | Аналоги 2-феноксипиримидинона |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| EP3180340B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| WO2016145032A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| WO2020146449A1 (en) * | 2019-01-08 | 2020-07-16 | Texas Tech University System | Small molecule analogs of the protein e4orf1 in the treatment and prevention of metabolic disorders |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0364598A4 (en) * | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
| US5202328A (en) * | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| ES2184960T3 (es) * | 1996-05-15 | 2003-04-16 | Pfizer | Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas. |
| CA2288735A1 (en) | 1997-05-08 | 1998-11-12 | Agrevo Uk Limited | Fungicides |
| US6627755B1 (en) * | 1997-06-09 | 2003-09-30 | Pfizer Inc | Quinazolin-4-one AMPA antagonists |
| IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| US6323208B1 (en) * | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| WO2002026718A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceutical, Inc. | Bicyclic pyrimidin-4-one based inhibitors of factor xa |
| MXPA03004926A (es) * | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas. |
| CZ20032561A3 (cs) | 2001-03-26 | 2003-12-17 | Novartis Ag | Deriváty pyridinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
| EP1430161B1 (de) * | 2001-09-28 | 2005-06-15 | DaimlerChrysler AG | Hochfester duplex-/triplex-leichtbaustahl und seine verwendung |
| WO2003055848A2 (en) | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
| AU2003241453A1 (en) | 2002-05-17 | 2003-12-02 | Janssen Pharmaceutica N.V. | Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| WO2003106435A1 (en) | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
| WO2004028440A2 (en) | 2002-09-24 | 2004-04-08 | Bayer Healthcare Ag | Vr1 antagonists for the treatment of urological disorders |
| GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| US20040242568A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| EP1687306A1 (en) * | 2003-11-14 | 2006-08-09 | MERCK SHARP & DOHME LTD. | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| GB0326633D0 (en) | 2003-11-14 | 2003-12-17 | Merck Sharp & Dohme | Therapeutic agents |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
| AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| AU2006244027A1 (en) * | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilloid-1 receptor (VR1) |
| GB0509573D0 (en) * | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| CN1318429C (zh) * | 2005-07-25 | 2007-05-30 | 华中师范大学 | 具有杀菌活性的取代噻吩并[3',2':5,6]吡啶并[4,3－d]嘧啶－4(3H)－酮及制备 |
| US20100152209A1 (en) | 2005-11-04 | 2010-06-17 | Hydra Biosciences Inc. | Compounds for Modulating TRPV3 Function |
| US20080090845A1 (en) * | 2006-08-23 | 2008-04-17 | Neurogen Corporation | Haloalkyl-substituted pyrimidinone derivatives |
| EA200900330A1 (ru) | 2006-08-23 | 2009-08-28 | Ньюроджен Корпорейшн | Аналоги 2-феноксипиримидинона |
| CA2668579A1 (en) * | 2006-11-06 | 2008-06-05 | Neurogen Corporation | Cis-cyclohexyl substituted pyrimidinone derivatives |
| WO2008156607A1 (en) | 2007-06-12 | 2008-12-24 | Neurogen Corporation | Substituted pyrimidinones |
| WO2009100403A1 (en) | 2008-02-07 | 2009-08-13 | Neurogen Corporation | Substituted aryl pyrimidinones |
| WO2009121036A2 (en) | 2008-03-27 | 2009-10-01 | Neurogen Corporation | Substituted aryl pyrimidinone derivatives |
-
2007
- 2007-08-22 EA EA200900330A patent/EA200900330A1/ru unknown
- 2007-08-22 AU AU2007288203A patent/AU2007288203B2/en not_active Ceased
- 2007-08-22 ZA ZA200901163A patent/ZA200901163B/xx unknown
- 2007-08-22 KR KR1020097005810A patent/KR20090043583A/ko not_active Withdrawn
- 2007-08-22 JP JP2009525630A patent/JP5421108B2/ja not_active Expired - Fee Related
- 2007-08-22 US US11/895,286 patent/US8003656B2/en active Active
- 2007-08-22 ES ES07811503T patent/ES2399928T3/es active Active
- 2007-08-22 CN CNA2007800309530A patent/CN101506210A/zh active Pending
- 2007-08-22 CN CN201410468406.2A patent/CN104292229A/zh active Pending
- 2007-08-22 BR BRPI0716582-0A2A patent/BRPI0716582A2/pt not_active IP Right Cessation
- 2007-08-22 MX MX2009002066A patent/MX2009002066A/es unknown
- 2007-08-22 WO PCT/US2007/018654 patent/WO2008024438A2/en not_active Ceased
- 2007-08-22 TW TW096131019A patent/TW200825089A/zh unknown
- 2007-08-22 EP EP07811503A patent/EP2061794B1/en active Active
- 2007-08-22 CA CA2660957A patent/CA2660957C/en not_active Expired - Fee Related
-
2009
- 2009-02-15 IL IL197043A patent/IL197043A0/en unknown
- 2009-02-20 SV SV2009003173A patent/SV2009003173A/es not_active Application Discontinuation
- 2009-02-20 NI NI200900023A patent/NI200900023A/es unknown
- 2009-02-23 GT GT200900040A patent/GT200900040A/es unknown
- 2009-03-18 CO CO09028167A patent/CO6150167A2/es unknown
- 2009-03-20 CR CR10675A patent/CR10675A/es not_active Application Discontinuation
- 2009-03-20 NO NO20091182A patent/NO20091182L/no not_active Application Discontinuation
- 2009-03-23 MA MA31732A patent/MA30720B1/fr unknown
-
2011
- 2011-08-22 US US13/215,195 patent/US8759361B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8759361B2 (en) | 2014-06-24 |
| EP2061794A4 (en) | 2010-09-08 |
| JP5421108B2 (ja) | 2014-02-19 |
| US8003656B2 (en) | 2011-08-23 |
| AU2007288203B2 (en) | 2013-01-17 |
| WO2008024438A3 (en) | 2008-11-27 |
| GT200900040A (es) | 2010-03-16 |
| IL197043A0 (en) | 2009-11-18 |
| CA2660957C (en) | 2016-10-11 |
| ES2399928T3 (es) | 2013-04-04 |
| KR20090043583A (ko) | 2009-05-06 |
| WO2008024438A2 (en) | 2008-02-28 |
| BRPI0716582A2 (pt) | 2013-10-08 |
| EP2061794A2 (en) | 2009-05-27 |
| NI200900023A (es) | 2010-03-05 |
| US20120208829A1 (en) | 2012-08-16 |
| EP2061794B1 (en) | 2012-12-05 |
| AU2007288203A1 (en) | 2008-02-28 |
| MA30720B1 (fr) | 2009-09-01 |
| JP2010502576A (ja) | 2010-01-28 |
| SV2009003173A (es) | 2010-08-10 |
| CN104292229A (zh) | 2015-01-21 |
| EA200900330A1 (ru) | 2009-08-28 |
| US20090069347A1 (en) | 2009-03-12 |
| CR10675A (es) | 2009-04-17 |
| NO20091182L (no) | 2009-05-14 |
| ZA200901163B (en) | 2010-08-25 |
| TW200825089A (en) | 2008-06-16 |
| CN101506210A (zh) | 2009-08-12 |
| CA2660957A1 (en) | 2008-02-28 |
| MX2009002066A (es) | 2009-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6241110A2 (es) | Analogos deamidas heteroarilicas como antagonistas del p2x7 | |
| CO6190582A2 (es) | Derivados de heteroarilamida | |
| NI201100181A (es) | Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos | |
| PE20240022A1 (es) | Derivados de fosforo como nuevos inhibidores de sos1 | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| PE20190329A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| CO6241157A2 (es) | "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9" | |
| CO6321230A2 (es) | Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga | |
| AR062679A1 (es) | Derivados de eter diarilico y usos de los mismos | |
| CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| CO2021003115A2 (es) | Inhibidores de sarcómeros cardíacos | |
| AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
| ES2637167T3 (es) | Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirimidina y su uso como moduladores de los receptores de C5a | |
| CO6251294A2 (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR067058A1 (es) | Oxazolidinonas sustituidas y su uso para preparar medicamentos | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica |